TY - JOUR
T1 - Heterotypic 3D pancreatic cancer model with tunable proportion of fibrotic elements
AU - Tanaka, Hiroyoshi Y.
AU - Kurihara, Tsuyoshi
AU - Nakazawa, Takuya
AU - Matsusaki, Michiya
AU - Masamune, Atsushi
AU - Kano, Mitsunobu R.
N1 - Funding Information:
The authors deeply thank Dr. Hiromi Matsubara and Dr. Aiko Ogawa (National Hospital Organization Okayama Medical Center) for the generous provision of experimental facilities and reagents, Mrs. Kazuko Kado (National Hospital Organization Okayama Medical Center) for technical assistance, and Dr. Kazuki Nagashima (Stanford University) for editorial assistance. Further thanks to past and present members of the lab, especially Ms. Natsumi Nakao for her technical assistance and artistic input in the graphical abstract. This study was supported in part by Grant-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Science (HYT: 20K16989, MM: 17H02099, AM: 19H03631, and MRK: 26293119 and 18H02797), Okayama University (HYT and MRK), the Pancreas Research Foundation of Japan (HYT and MRK), the KAWASAKI Foundation for Medical Science and Medical Welfare (HYT), and JSPS Core-to-Core Program A. Advanced Research Networks (HYT). HYT was supported by a Ph.D. scholarship from the Takeda Science Foundation.
Funding Information:
The authors deeply thank Dr. Hiromi Matsubara and Dr. Aiko Ogawa (National Hospital Organization Okayama Medical Center) for the generous provision of experimental facilities and reagents, Mrs. Kazuko Kado (National Hospital Organization Okayama Medical Center) for technical assistance, and Dr. Kazuki Nagashima (Stanford University) for editorial assistance. Further thanks to past and present members of the lab, especially Ms. Natsumi Nakao for her technical assistance and artistic input in the graphical abstract. This study was supported in part by Grant-in-Aid for Scientific Research (KAKENHI) from the Japan Society for the Promotion of Science ( HYT: 20K16989 , MM: 17H02099 , AM: 19H03631 , and MRK: 26293119 and 18H02797 ), Okayama University (HYT and MRK), the Pancreas Research Foundation of Japan (HYT and MRK), the KAWASAKI Foundation for Medical Science and Medical Welfare (HYT), and JSPS Core-to-Core Program A. Advanced Research Networks (HYT). HYT was supported by a Ph.D. scholarship from the Takeda Science Foundation .
Publisher Copyright:
© 2020 Elsevier Ltd
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/8
Y1 - 2020/8
N2 - Pancreatic ductal adenocarcinoma (PDAC) is an often lethal disease characterized by a dense, fibrotic stroma. However, the lack of relevant preclinical models that recapitulate the characteristic histopathology of human PDAC in vitro impedes the development of novel therapies. The amount of stromal elements differ largely within and between patients, but in vitro models of human PDAC often do not account for this heterogeneity. Indeed, analyses of human PDAC histopathology revealed that the proportion of stroma ranged from 40 to 80% across patients. We, therefore, generated a novel 3D model of human PDAC, consisting of co-cultured human PDAC tumor cells and fibroblasts/pancreatic stellate cells, in which the proportion of fibrotic elements can be tuned across the clinically observed range. Using this model, we analyzed the signaling pathways involved in the differentiation of myofibroblasts, a characteristic subpopulation of fibroblasts seen in PDAC. We show that both YAP and SMAD2/3 in fibroblasts are required for myofibroblastic differentiation and that both shared and distinct signaling pathways regulate the nuclear localization of these factors during this process. Our novel model will be useful in promoting the understanding of the complex mechanisms by which the fibrotic stroma develops and how it might be therapeutically targeted.
AB - Pancreatic ductal adenocarcinoma (PDAC) is an often lethal disease characterized by a dense, fibrotic stroma. However, the lack of relevant preclinical models that recapitulate the characteristic histopathology of human PDAC in vitro impedes the development of novel therapies. The amount of stromal elements differ largely within and between patients, but in vitro models of human PDAC often do not account for this heterogeneity. Indeed, analyses of human PDAC histopathology revealed that the proportion of stroma ranged from 40 to 80% across patients. We, therefore, generated a novel 3D model of human PDAC, consisting of co-cultured human PDAC tumor cells and fibroblasts/pancreatic stellate cells, in which the proportion of fibrotic elements can be tuned across the clinically observed range. Using this model, we analyzed the signaling pathways involved in the differentiation of myofibroblasts, a characteristic subpopulation of fibroblasts seen in PDAC. We show that both YAP and SMAD2/3 in fibroblasts are required for myofibroblastic differentiation and that both shared and distinct signaling pathways regulate the nuclear localization of these factors during this process. Our novel model will be useful in promoting the understanding of the complex mechanisms by which the fibrotic stroma develops and how it might be therapeutically targeted.
KW - 3D culture
KW - Cancer-associated fibroblast
KW - Myofibroblast
KW - Pancreatic cancer
KW - Pancreatic stellate cell
KW - Tumor stroma
UR - http://www.scopus.com/inward/record.url?scp=85084171260&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084171260&partnerID=8YFLogxK
U2 - 10.1016/j.biomaterials.2020.120077
DO - 10.1016/j.biomaterials.2020.120077
M3 - Article
C2 - 32388166
AN - SCOPUS:85084171260
SN - 0142-9612
VL - 251
JO - Biomaterials
JF - Biomaterials
M1 - 120077
ER -